Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Moodys
Julphar
Daiichi Sankyo
Cipla
Teva
Dow
Fuji
Healthtrust
Deloitte

Generated: August 18, 2017

DrugPatentWatch Database Preview

Lederle Company Profile

« Back to Dashboard

What is the competitive landscape for LEDERLE, and what generic and branded alternatives to LEDERLE drugs are available?

LEDERLE has ninety-six approved drugs.



Summary for Applicant: Lederle

Patents:0
Tradenames:49
Ingredients:48
NDAs:96
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lederle
AMITRIPTYLINE HYDROCHLORIDE
amitriptyline hydrochloride
TABLET;ORAL087367-001May 3, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lederle
NEPTAZANE
methazolamide
TABLET;ORAL011721-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Lederle
ACETAMINOPHEN AND CODEINE PHOSPHATE
acetaminophen; codeine phosphate
TABLET;ORAL087141-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lederle
ACHROMYCIN
procaine hydrochloride; tetracycline hydrochloride
INJECTABLE;INJECTION050276-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lederle
DOLENE AP-65
acetaminophen; propoxyphene hydrochloride
TABLET;ORAL085100-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Lederle

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lederle
ASENDIN
amoxapine
TABLET;ORAL018021-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Lederle
ASENDIN
amoxapine
TABLET;ORAL018021-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Lederle
ASENDIN
amoxapine
TABLET;ORAL018021-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Lederle
ASENDIN
amoxapine
TABLET;ORAL018021-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Lederle
ASENDIN
amoxapine
TABLET;ORAL018021-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for LEDERLE drugs

Drugname Dosage Strength Tradename Submissiondate
cefixime
for Oral Suspension500 mg/5 mL
SUPRAX
7/22/2014

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Argus Health
McKesson
Deloitte
Harvard Business School
Citi
Mallinckrodt
McKinsey
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot